[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.166.48.3. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Editorial
July 25, 2012

Inflammation, Immune Activation, and CVD Risk in Individuals With HIV Infection

Author Affiliations

Author Affiliations: University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin (Dr Stein); and University of California, San Francisco School of Medicine, San Francisco (Dr Hsue).

JAMA. 2012;308(4):405-406. doi:10.1001/jama.2012.8488

Antiretroviral therapy (ART) prolongs life, but individuals infected with human immunodeficiency virus (HIV) have a shorter life span than their uninfected counterparts and a greater than expected risk of cardiovascular disease (CVD).1,2 Part of the increased CVD risk associated with HIV infection can be attributed to an increased burden of traditional risk factors such as cigarette smoking, as well as the effects of ART on lipids, insulin resistance, and body composition. However, increasing evidence suggests that chronic inflammation and immune activation may play key roles in HIV-associated CVD.

First Page Preview View Large
First page PDF preview
First page PDF preview
×